Phaseline

Companies › BioAegis Therapeutics

BioAegis Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease, Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rhu-pGSN
Recombinant human gelsolin - actin-scavenging protein that reduces inflammatory cell damag
GSNPhase 2Acute Respiratory Distress SyndromeOct 2027
Recombinant human plasma gelsolin
Plasma gelsolin acts as a scavenger of actin released from damaged cells and modulates inf
GSNPhase 2Decompression Sickness–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06216366Recombinant human plasma gelsolinPhase 2Decompression SicknessOtherSep 2025
NCT05947955Rhu-pGSNPhase 2Acute Respiratory Distress SyndromeInfectious diseaseOct 2027

Targets

GSN (2)

Companies with the same targets

–

Companies built like this

Freya Biosciences ApS Aligos Therapeutics BioVersys SAS Meitheal Pharmaceuticals Shanghai Yidian Pharmaceutical Technology Development

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.